Conduit Pharms Stock Price, News & Analysis

Conduit Pharmaceuticals (NASDAQ:CDT) has filed four new patent applications for its key assets AZD1656 and AZD5658, including the company's first composition of matter patent for AZD5658. The patents were developed through AI-driven analysis in partnership with Sarborg Limited, focusing on combinations of Conduit's lead assets with existing therapies.

The patent filings represent a significant expansion of Conduit's intellectual property portfolio in autoimmune and inflammatory conditions. The company aims to advance and license these differentiated, IP-rich pharmaceutical assets while maintaining its capital-efficient development model.

Conduit Pharmaceuticals (NASDAQ: CDT) has entered a strategic joint development agreement with Manoira Corporation to evaluate its glucokinase activators AZD1656 and AZD5658 for animal health applications. The collaboration focuses on developing treatments for animal osteoarthritis, with Manoira utilizing its reformulation expertise to generate valuable cross-species insights. The agreement allows Conduit to maintain 100% ownership of intellectual property while gaining access to the $15 billion animal health market. Manoira will fund all development activities in exchange for $500,000 in Conduit stock (154,799 shares at $3.23 per share). The partnership aims to accelerate human clinical programs through cost-efficient preclinical data generation while exploring potential combination therapies with Manoira's patented CBDA co-crystal.

Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a clinical-stage life science company, has received approval from Nasdaq to transfer its common stock listing to the Nasdaq Capital Market. The transfer will be effective at market open on May 23, 2025. This approval follows the Company's confirmation of compliance with Bid Price and Equity Requirements, as previously announced on May 21, 2025.

Conduit Pharmaceuticals (NASDAQ: CDT) has successfully regained compliance with Nasdaq's listing requirements, specifically the minimum bid price requirement and stockholders' equity requirement. The clinical-stage life science company will continue to be listed and traded on the Nasdaq Stock Market.

The Nasdaq Hearing Panel has implemented a one-year Discretionary Panel Monitor starting May 15, 2025, to ensure long-term compliance with listing requirements. During this monitoring period, CDT maintains the right to request a hearing if it receives any future delisting determination letters.

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) has announced a 1-for-15 reverse stock split of its common stock, effective May 19, 2025, at 5:00 pm ET. The split was approved by stockholders on May 5, 2025, and trading on a split-adjusted basis will begin on May 20, 2025, under the same ticker "CDT".

Following the split, the outstanding shares will be reduced to approximately 755,900. The par value will remain at $0.0001 per share. Proportional adjustments will be made to equity awards, convertible securities, and warrants. No fractional shares will be issued, with stockholders entitled to fractional shares receiving proportional cash payments instead.

Conduit Pharmaceuticals (NASDAQ: CDT) has secured a composition of matter patent from the Korean Intellectual Property Office (KIPO) for AZD1656, its lead asset targeting autoimmune diseases. The Glucokinase Activator's patent approval in South Korea follows recent grants in the U.S., Japan, and Australia, strengthening the company's global intellectual property position. This strategic milestone is particularly significant as South Korea is often commercially partnered with Japan in licensing and distribution arrangements by major Western pharmaceutical companies, enhancing Conduit's presence in the valuable Asia-Pacific pharmaceutical market.

Conduit Pharmaceuticals (NASDAQ: CDT) has filed a new composition of matter patent for AZD5904, a clinical-stage myeloperoxidase (MPO) inhibitor. The patent covers a novel solid form with enhanced solubility, enabling new formulation strategies and potentially securing up to 20 years of intellectual property protection. AZD5904, originally developed by AstraZeneca for multiple sclerosis and COPD, has completed five Phase 1 studies showing strong target engagement without major safety concerns. The compound has shown promising results in preclinical models of idiopathic male infertility (IMI), improving sperm motility and penetration. This development expands AZD5904's potential beyond its previous IP coverage limited to male infertility applications, positioning it for broader clinical development opportunities in conditions where MPO-driven inflammation plays a role.

Conduit Pharmaceuticals (Nasdaq: CDT) announced significant leadership changes as founder Dr. Andrew Regan takes over as Chief Executive Officer, replacing Dr. David Tapolczay who will transition to Head of Strategy & Licensing. Dr. Tapolczay will focus on out-licensing deals for tapinarof patents.

Dr. Regan brings extensive entrepreneurial experience, including successful ventures like Hobson Plc (sold for £154 million), founding shareholder of Asos plc (reached £4.8 billion market cap), and Imperial Energy (acquired for £1.4 billion). He holds a PhD in bio-inspired algorithm development for financial market forecasting.

The company also announced that Faith Charles will step down from the Board of Directors. Under the new leadership, Conduit aims to maximize shareholder value through licensing opportunities, creating new 20-year Composition-of-Matter patents, and utilizing AI and Cybernetics in collaboration with Sarborg for drug repurposing.

Conduit Pharmaceuticals (Nasdaq: CDT) has filed two groundbreaking patents for VTAMA® (tapinarof), including a dual active cocrystal formulation that combines the drug with a complementary substance to address both therapeutic needs and side effects in inflammatory skin conditions.

The new patents come as VTAMA® approaches its 2027 exclusivity expiration. The innovation aims to enhance patient benefits by addressing symptoms like pain and itch, while extending patent protection and expanding therapeutic applications. This development is particularly significant as tapinarof enters clinical trials for cutaneous lupus and shows promise in other inflammatory and autoimmune indications.

The strategic timing aligns with the growing anti-inflammatory therapeutics market, projected to exceed $233.6 billion by 2032. The company is actively seeking partnerships to leverage this breakthrough IP while continuing to advance its broader pipeline.